Tissue and circulating proprotein convertase subtilisin/Kexin type 9 (PCSK9) as promising prognostic biomarkers for curative-intent colorectal liver metastases resection: A case-control study

Key Points

• Tissue and plasma pcsk9 levels predict outcomes after curative resection of colorectal liver metastases.
• The study shows a promising link between pcsk9 expression and improved prognostic indicators in treatment.
• Case-control methodology underscores the significance of biomarkers like pcsk9 in surgical decision-making.
• Findings call for further validation of pcsk9 as a reliable prognostic tool in clinical practice.